SABCS 2021: PHOEBE Update Confirms Overall Survival Benefit of Pyrotinib in HER2-Positive Metastatic Breast Cancer
This is a good option in regions where trastuzumab-emtansine is not approved for metastatic disease
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.